Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Miss Liandre van der Merwe
Liandre.vanderMerwe@lshtm.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Long-chain n-3 polyunsaturated fatty acids in relation to gut integrity, growth failure and cognitive development of rural African infants
Back

Long-chain n-3 polyunsaturated fatty acids in relation to gut integrity, growth failure and cognitive development of rural African infants

Not Recruiting

Open to: All Genders

Age: Child

London

Medical Conditions

Infant growth and gut integrity

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Not provided at time of registration

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

02 Apr 2007 04 Apr 2008

Publications

2013 Results article in http://www.ncbi.nlm.nih.gov/pubmed/23221579 results

Interventional

Intervention Type : Drug
Intervention Description : Current interventions as of 12/01/2009: The active group will receive 2 ml per day of highly purified fish oil (200 mg docosahexaenoic acid [DHA] and 300 mg eicosapentaenoic acid [EPA]) supplied by Nordic Naturals Inc, USA, for six months. The dosage was designed to achieve a substantial increase in plasma n-3 PUFA to both eliminate any existing deficiencies and to elicit a therapeutic response.

Previous interventions:The active group will receive 2 ml per day of highly purified fish oil (500 mg docosahexaenoic acid [DHA] and 500 mg eicosapentaenoic acid [EPA]) supplied by Nordic Naturals Inc, USA, for six months. The dosage was designed to achieve a substantial increase in plasma n-3 PUFA to both eliminate any existing deficiencies and to elicit a therapeutic response.




You can take part if:



You may not be able to take part if:


1. Severe congenital abnormalities that could affect growth and development2. Known HIV infection

Added as of 12/01/2009:3. Infants from multiple births


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Medical Research Council International Nutrition Group
    London
    WC1E 7HT

This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.

Miss Liandre van der Merwe
Liandre.vanderMerwe@lshtm.ac.uk



The study is sponsored by Medical Research Council (UK) and funded by Medical Research Council (UK); Overseas Research Students Awards Scheme (ORSAS) (UK); Ernest Oppenheimer Memorial Trust (South Africa).



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN66645725
Last updated 12 December 2012

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top